U.S. markets open in 59 minutes
  • S&P Futures

    4,540.25
    +16.00 (+0.35%)
     
  • Dow Futures

    35,021.00
    +111.00 (+0.32%)
     
  • Nasdaq Futures

    15,147.75
    +114.25 (+0.76%)
     
  • Russell 2000 Futures

    2,065.90
    +6.70 (+0.33%)
     
  • Crude Oil

    86.17
    -0.79 (-0.91%)
     
  • Gold

    1,841.50
    -1.70 (-0.09%)
     
  • Silver

    24.24
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1349
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.08
    +0.29 (+1.27%)
     
  • GBP/USD

    1.3619
    +0.0007 (+0.05%)
     
  • USD/JPY

    114.2360
    -0.1170 (-0.10%)
     
  • BTC-USD

    42,027.38
    -196.09 (-0.46%)
     
  • CMC Crypto 200

    997.88
    +3.13 (+0.31%)
     
  • FTSE 100

    7,576.64
    -13.02 (-0.17%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.